Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2020

01-09-2020 | Thrombocytopenia | UNM CLINICAL CASE CONFERENCES

Ascites in the “TAFRO” Syndrome: Does the Squeeze Make the Juice?

Authors: Aamer Abbass, Sameen Khalid, Laura Toth, Steven Eberhardt, Denis McCarthy

Published in: Digestive Diseases and Sciences | Issue 9/2020

Login to get access

Excerpt

A 41-year-old healthy female underwent cholecystectomy due to symptomatic gallstone related acute cholecystitis. A week later she was readmitted with fatigue, low grade fever, worsening pallor, generalized edema including bilateral leg swelling and abdominal distension with pain. Laboratory evaluation showed mild normocytic anemia (Hgb 7 g/dL [12–16 g/dL]), mean corpuscular volume 92 fL (80–100 fL), mild leukocytosis with WBC count 12,000/µL (4000–11,000/µL), thrombocytopenia (platelet count 55,000/µL [150,000–400,000/µL]). Comprehensive metabolic panel showed normal serum electrolytes, blood urea nitrogen, creatinine, and liver profile, except for low serum total protein of 5.1 g/dL (6.1–8.2 g/dL) and hypoalbuminemia (albumin 2.4 g/dL [3.4–4.7 g/dL]). Urinalysis showed proteinuria and an elevated random protein-to-creatinine ratio of 3.8. A 24-h urine collection revealed an elevated total protein of 3.1 gm/24 h, consistent with nephrotic range proteinuria. A contrast computerized scan (CT) of chest, abdomen and pelvis showed moderate bilateral pleural effusions, and moderate ascites: no other abnormality was noted in the chest, abdomen, or pelvis. Diagnostic and therapeutic paracenteses were performed draining about 3000 ml of straw-colored fluid. Analysis showed a serum-ascites-albumin gradient (SAAG) of 1.9 g/dL with a normal cell count and negative cytology. An extensive serologic and autoimmune investigation was undertaken for anemia, hypoalbuminemia, and thrombocytopenia. Anti-nuclear antibody (ANA) was mildly elevated at 1:160 titer (homogenous pattern). Anti-Smith, anti-Jo1, anti-smooth muscle antigen (ASMA), antimitochondrial antibody (AMA), anti–liver-kidney microsomal antibody (LKM), anti-neutrophilic cytoplasmic antibody (ANCA), aldolase, anti-synthetase, anti-ribonuclear protein, anti-dsDNA, anti-myeloperoxidase, anti-dermatomyositis antibody panel were negative. Infectious workup including syphilis, human immunodeficiency virus, EBV, HSV, CMV, parvovirus B19, and antistreptolysin O (ASO) titer are unremarkable. Hematologic tests for haptoglobin, ADAMTS 13, cryoglobulins, serum and urine protein electrophoresis and lactate dehydrogenase were all negative. A CT of abdomen and pelvis (without contrast) now showed a large volume of ascites, moderate bilateral pleural effusions and, for the first time, some mildly prominent retroperitoneal, pelvic, and inguinal lymph nodes. Kidney biopsy revealed a global, diffuse thrombotic micro-angiopathy; the bone marrow, though hypercellular for age, displayed no dysplastic changes, no increase in blast cells: no monoclonal B-cells and abnormal T-cells were absent. Based on these findings, a diagnosis of thrombotic thrombocytopenic purpura (TTP) was made, and therapy was started with high doses of intravenous dexamethasone and repeated plasma exchanges. The patient, however, did not respond, and after a multi-disciplinary meeting between rheumatology, hematology, and nephrology services, the diagnosis was revised to atypical/complement mediated hemolytic uremic syndrome (HUS) that was treated with eculizumab. Blood platelet and hemoglobin concentrations improved, and renal dysfunction and proteinuria gradually resolved. The ascites, however, persisted, which necessitated diuretic therapy with furosemide and spironolactone. …
Literature
1.
go back to reference Castleman B, Iverson I, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer. 1956;9:822–830.CrossRef Castleman B, Iverson I, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer. 1956;9:822–830.CrossRef
2.
go back to reference Dispenzieri A, Fajgenbaum DC. Overview of Castleman Disease. Blood. 2020. 10.1182/blood.2019000931. Accessed on 4 Mar 2020 Dispenzieri A, Fajgenbaum DC. Overview of Castleman Disease. Blood. 2020. 10.1182/blood.2019000931. Accessed on 4 Mar 2020
3.
go back to reference Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–1657.CrossRef Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–1657.CrossRef
4.
go back to reference Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–226.CrossRef Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–226.CrossRef
5.
go back to reference Alhoulaiby S, Ahmad B, Alrstom A, Kudsi M. Castleman’s disease with TAFRO syndrome: a case report from Syria, Oxf Med Case Rep. 2017; 2017(6):omx021. Accessed on 4 May 2020. Alhoulaiby S, Ahmad B, Alrstom A, Kudsi M. Castleman’s disease with TAFRO syndrome: a case report from Syria, Oxf Med Case Rep. 2017; 2017(6):omx021. Accessed on 4 May 2020.
6.
go back to reference Takai K, Nikkuni K, Shibuya H, Hashidate H, Ketsueki R. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Jpn J Clin Hematol. 2010;51:320–325. Takai K, Nikkuni K, Shibuya H, Hashidate H, Ketsueki R. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Jpn J Clin Hematol. 2010;51:320–325.
7.
go back to reference Masaki Y, Kawabata H, Takai K, Kojima M, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:68.CrossRef Masaki Y, Kawabata H, Takai K, Kojima M, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:68.CrossRef
9.
go back to reference Yan J, Behnia F, Payne T, Libby E. Recurrent ascites in Castleman-Kojima disease (TAFRO syndrome): a mimic of lymphoma in FDG PET-CT imaging. J Nucl Med. 2014. Abstract accessed online on 4 3Mar 020. Yan J, Behnia F, Payne T, Libby E. Recurrent ascites in Castleman-Kojima disease (TAFRO syndrome): a mimic of lymphoma in FDG PET-CT imaging. J Nucl Med. 2014. Abstract accessed online on 4 3Mar 020.
10.
go back to reference Gupta MK, Magu SK, Behl A. Multicentric castleman’s disease. Med J Armed Forces India. 2002;58:250–252.CrossRef Gupta MK, Magu SK, Behl A. Multicentric castleman’s disease. Med J Armed Forces India. 2002;58:250–252.CrossRef
11.
go back to reference Pinto AL, Gomez M, Cipriano MA, Ribeiro ML. Non-cirrhotic portal hypertension associated with multicentric Castleman’s disease: a case report. Acta Oncol. 2018;57:703–705.CrossRef Pinto AL, Gomez M, Cipriano MA, Ribeiro ML. Non-cirrhotic portal hypertension associated with multicentric Castleman’s disease: a case report. Acta Oncol. 2018;57:703–705.CrossRef
12.
go back to reference Tsurumi H, Fujigaki Y, Yamamoto T, Lino R, et al. Remission of refractory ascites and discontinuation of hemodialysis after additional rituximab to long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med. 2018;57:1433–1438.CrossRef Tsurumi H, Fujigaki Y, Yamamoto T, Lino R, et al. Remission of refractory ascites and discontinuation of hemodialysis after additional rituximab to long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med. 2018;57:1433–1438.CrossRef
13.
go back to reference Tatekawa S, Umemura K, Fukuyama R, Kohno A, et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3:472–478.CrossRef Tatekawa S, Umemura K, Fukuyama R, Kohno A, et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3:472–478.CrossRef
Metadata
Title
Ascites in the “TAFRO” Syndrome: Does the Squeeze Make the Juice?
Authors
Aamer Abbass
Sameen Khalid
Laura Toth
Steven Eberhardt
Denis McCarthy
Publication date
01-09-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06433-w

Other articles of this Issue 9/2020

Digestive Diseases and Sciences 9/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.